Abstract:Lipoprotein(a) [Lp(a)] is a well-established risk factor for cardiovascular disease, predisposing to major cardiovascular events, including coronary heart disease, stroke, aortic valve calcification and abdominal aortic aneurysm. Lp(a) is differentiated from other lipoprotein molecules through apolipoprotein(a), which possesses atherogenic and antithrombolytic properties attributed to its structure. Lp(a) levels are mostly genetically predetermined and influenced by the size of LPA gene variants, with smaller isoforms resulting in a greater synthesis rate of apo(a) and, ultimately, elevated Lp(a) levels. As a result, serum Lp(a) levels may highly vary from extremely low to extremely high. Hyperlipoproteinemia(a) is defined as Lp(a) levels > 30 mg/dL in the US and >50 mg/dL in Europe. Because of its association with CVD, Lp(a) levels should be measured at least once a lifetime in adults. The ultimate goal is to identify individuals with increased risk of CVD and intervene accordingly. Traditional pharmacological interventions like niacin, statins, ezetimibe, aspirin, PCSK-9 inhibitors, mipomersen, estrogens and CETP inhibitors have not yet yielded satisfactory results. The mean Lp(a) reduction, if any, is barely 50% for all agents, with statins increasing Lp(a) levels, whereas a reduction of 80-90% appears to be required to achieve a significant decrease in major cardiovascular events. Novel RNA-interfering agents that specifically target hepatocytes are aimed in this direction. Pelacarsen is an antisense oligonucleotide, while olpasiran, LY3819469 and SLN360 are small interfering RNAs, all conjugated with a N-acetylgalactosamine molecule. Their ultimate objective is to genetically silence LPA, reduce apo(a) production and lower serum Lp(a) levels. Evidence thus so far demonstrates that monthly subcutaneous administration of a single dose yields optimal results with persisting substantial reductions in Lp(a) levels, potentially enhancing CVD risk reduction. The Lp(a) reduction achieved with novel RNA agents may exceed 95%. The results of ongoing and future clinical trials are eagerly anticipated, and it is hoped that guidelines for the tailored management of Lp(a) levels with these novel agents may not be far off.

Recent updates on therapeutic targeting of lipoprotein(a) with RNA interference

New insights into the therapeutic options to lower lipoprotein(a)

Therapeutic Potential of Lipoprotein(a) Inhibitors

Lipoprotein (a) as a Biomarker for Cardiovascular Diseases and Potential New Therapies to Mitigate Risk

Lp(a): A Rapidly Evolving Therapeutic Landscape

Advances in lipid-lowering therapy through gene-silencing technologies

Novel Pharmacological Therapies for the Management of Hyperlipoproteinemia(a)

Efficacy of Traditional Anti-lipidemic Drugs in Lowering Lipoprotein(a) Levels: A Systematic Review

Lepodisiran, an siRNA targeting lipoprotein(a) for the potential future treatment of cardiovascular disease

Lp(a) in the Pathogenesis of Aortic Stenosis and Approach to Therapy with Antisense Oligonucleotides or Short Interfering RNA

Lentiviral-mediated RNA Interference of Lipoprotein-Associated Phospholipase A2 Ameliorates Inflammation and Atherosclerosis in Apolipoprotein E-deficient Mice

Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)

The Future of Lipid-lowering Therapy

RNA interference in the era of nucleic acid therapeutics

RNA interference-based therapies for atherosclerosis: Recent advances and future prospects

Non-viral Nucleic Acid Therapeutics: Revolutionizing the Landscape of Atherosclerotic Treatment

In Vitro Inhibition of Lipoprotein Lipase Gene Expression by RNA Interference

RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies

Lp(a): a New Pathway to Target?

RNA Therapeutics - Research and Clinical Advancements

Lipoprotein(a): A Review of Risk Factors, Measurements, and Novel Treatment Modalities